Telomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical Type 2 Diabetes Model

▤ Summary

Telomir Pharmaceuticals announced a peer-reviewed publication showing that Telomir-Zn improved insulin sensitivity and glucose homeostasis in a zebrafish model of type 2 diabetes. The study reported dose-dependent reductions in fasting glucose, insulin, and HOMA-IR after 14 days of treatment. The company says the findings support its metal-homeostasis mechanism and add scientific backing to its broader clinical program in oncology and metabolic disease. Telomir also noted that Telomir-Zn has already received FDA IND clearance for a Phase 1/2 trial in advanced or metastatic triple-negative breast cancer.

▦ Linked Companies